Optimal antithrombotic treatment for percutaneous coronary intervention

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Atherosclerotic vascular disease necessitates percutaneous interventions.
• Anti-platelet and anti-thrombotic agents are crucial for minimizing procedural complications.
• Optimal antithrombotic therapy in percutaneous coronary interventions (PCI) requires careful consideration of various agents.

Purpose of the Study:

• To provide a current overview of optimal adjunctive antithrombotic therapy for PCI.
• To discuss anticoagulant agents (unfractionated heparin, low-molecular weight heparins, direct thrombin inhibitors) and antiplatelet agents (aspirin, thienopyridines, glycoprotein IIb/IIIa antagonists).
• To offer evidence-based recommendations for procedural anticoagulation based on patient risk stratification.

Main Methods:

• Review of current literature on antithrombotic agents used in PCI.
• Discussion of the coagulation process and mechanisms of action of key pharmacological agents.
• Analysis of clinical trial evidence for anticoagulant and antiplatelet therapies in PCI.

Main Results:

• Detailed presentation of anticoagulant and antiplatelet agents used adjunctively in PCI.
• Summary of evidence from recent clinical trials.
• Recommendations for procedural anticoagulation stratified by patient risk (low, not-low, and high risk).

Conclusions:

• Individualized decision-making by interventional cardiologists is paramount for determining optimal antithrombotic therapy.
• Appropriate dosing recommendations for employed agents are provided.
• The review aims to guide clinicians in selecting the most effective antithrombotic strategies for PCI.